New Research from NetApp Finds One in Five Companies Unable to Recover Data After Cyberattack
Survey of cybersecurity leaders highlights the importance of data classification in enhancing cyber resilience
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced the release of its latest report analyzing the state of cybersecurity and offering actionable insights to help organizations strengthen their cyber resiliency. The Futurum Group study, "Cloud, Complexity, AI: The Triple Threat Demanding New Cyber Resilience Strategies" sponsored by NetApp, provides a comprehensive analysis of evolving cyber threats and resiliency strategies.
The study, which surveyed over 1,300 cybersecurity leaders across industries worldwide, reveals that more than 54 percent of organizations experienced a cyberattack in the past 12 to 18 months, with one in five unable to recover lost data. The report highlights the urgent need for enterprises to leverage intelligent data infrastructure to address growing risks posed by sophisticated threats, operational complexity, and the challenges of hybrid multi-cloud environments.
"The findings clearly highlight the urgency for organizations to rethink their cybersecurity strategies in an era of escalating threats,” said Gagan Gulati, General Manager for Data Services at NetApp. "To reduce risks and ensure faster recovery, businesses must adopt an intelligent data strategy that prioritizes secure-by-design infrastructures, embedding security at the core of their data management approach. With data as a company’s most valuable asset, resilient storage solutions—such as those offered by NetApp—serve as the last line of defense in a comprehensive security strategy, safeguarding critical information and enabling long-term success in hybrid multi-cloud environments."
Key Findings:
- Cloud Security Risks: Misconfigurations and vulnerabilities in hybrid multi-cloud environments are now among the top threats, outpacing traditional attacks like ransomware. As organizations rely increasingly on hybrid cloud infrastructures, addressing these vulnerabilities is critical to maintaining data security and operational continuity.
- Tool Sprawl Challenges: Seventy percent of respondents use more than 40 cybersecurity tools, with 84 percent citing operational complexity as a major inhibitor to cyber resiliency. This complexity creates protection gaps and inefficiencies, underscoring the need for tool consolidation and integrated solutions to streamline operations.
- AI in Cybersecurity: Forty percent of organizations are leveraging AI for threat detection, with plans to expand its use for automating response and recovery. AI’s ability to identify and mitigate threats at scale is powerful, but balancing its use with managing false positives and ensuring robust human oversight is essential to its success.
- Data Classification is Key: Organizations with strong data classification frameworks recover from attacks more effectively, emphasizing its role as a cornerstone of cyber resiliency. This underscores the importance of embedding intelligent data infrastructure that not only classifies and protects data but also enables real-time anomaly detection and resilient recovery, enabling business continuity even in worst-case scenarios.
- Increased Investment: Over 90 percent of respondents plan to increase cybersecurity spend in the next 12 to 18 months, focusing on integrated and proactive solutions. Proactive investment can address the rising cost of cyberattacks and the growing complexity of threats, ensuring resilience and operational trust.
NetApp's Intelligent Data Infrastructure framework helps organizations address the cyber resiliency challenges revealed in this report by enabling organizations to take a proactive approach to data protection. By leveraging advanced data classification, AI-driven threat detection, and integrated security measures, organizations can more easily implement stringent governance practices, detect and respond to threats in real-time, and maintain compliance with evolving industry standards. As highlighted by the report, organizations with resilient data infrastructure have seen significant improvements in recovery times and overall data security, demonstrating that it is a critical component in modern cybersecurity strategies.
"This survey sheds light on the critical role of visibility and data-centric strategies in navigating the evolving cybersecurity landscape," said Daniel Newman, CEO at The Futurum Group. "By harnessing intelligent data infrastructure solutions, organizations can better protect their assets, ensure recovery, and thrive amidst disruption."
The report emphasizes the critical role of AI and integrated technologies as game-changers in combating increasingly sophisticated attack vectors. By leveraging AI alongside robust data classification and consolidated toolchains, enterprises can mitigate risks more effectively, reduce response times, and enhance visibility across sprawling hybrid multi-cloud environments.
To explore the full findings of the Cybersecurity Visibility Study 2024 and discover how IT and Security leaders are thinking about challenges and opportunities shaping the future of cyber resilience in the enterprise, visit https://www.netapp.com/media/120378-netapp-cloud-complexity-ai.pdf.
Methodology
In Fall 2024, NetApp collaborated with Futurum Research to conduct a comprehensive survey of over 1,300 cybersecurity leaders worldwide. The respondents included C-Level executives, Vice Presidents, and Directors in IT and Security, representing a diverse range of industries. The report draws on insights from the survey, as well as 15 in-depth interviews with selected decision-makers, offering a detailed analysis of the challenges and opportunities shaping the cybersecurity landscape today.
Additional Resources
- Empowering Cyber Resilience in the Digital Age
- The State of Cyber Resiliency 2024/2025
- Cyber Resilience: The Most Secure Storage on the Planet
About NetApp
NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
About The Futurum Group
The Futurum Group is the fastest- growing independent tech research, intelligence, media, and advisory firm. Its organic growth is driven by emerging technologies and innovation across its clientele of more than 260 global companies. Futurum covers twelve major technology sectors: AI & data analytics, cloud, telecom, policy, consumer electronics, enterprise applications, security, semiconductors, workplace collaboration, sustainability, and CX. In 2023 it has acquired half a dozen companies in areas of research, intelligence, media, and performance testing and validation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241204675480/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom